About: The Natural History of Influenza Infection in the Severely Immunocompromised vs Nonimmunocompromised Hosts

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Natural History of Influenza Infection in the Severely Immunocompromised vs Nonimmunocompromised Hosts Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The Natural History of Influenza Infection in the Severely Immunocompromised vs Nonimmunocompromised Hosts
Creator	Ademposi, Angela Athota, Rani Bristol, Tyler Czajkowski, Lindsay Fiorentino, Charles Hagey, Rachel Proudfoot, Kathleen Reed, Susan Shoham, Shmuel Voell, Jocelyn Taubenberger, Jeffery Memoli, Matthew
source	PMC
abstract	Introduction. Medical advances have led to an increase in the world's population of immunosuppressed individuals. The most severely immunocompromised patients are those who have been diagnosed with a hematologic malignancy, solid organ tumor, or who have other conditions that require immunosuppressive therapies and/or solid organ or stem cell transplants. Materials and methods. Medically attended patients with a positive clinical diagnosis of influenza were recruited prospectively and clinically evaluated. Nasal washes and serum were collected. Evaluation of viral shedding, nasal and serum cytokines, clinical illness, and clinical outcomes were performed to compare severely immunocompromised individuals to nonimmunocompromised individuals with influenza infection. Results. Immunocompromised patients with influenza had more severe disease/complications, longer viral shedding, and more antiviral resistance while demonstrating less clinical symptoms and signs on clinical assessment. Conclusions. Immunocompromised patients are at risk for more severe or complicated influenza induced disease, which may be difficult to prevent with existing vaccines and antiviral treatments. Specific issues to consider when managing a severely immunocompromised host include the development of asymptomatic shedding, multi-drug resistance during prolonged antiviral therapy, and the potential high risk of pulmonary involvement. Clinical trials registration, ClinicalTrials.gov identifier NCT00533182.
has issue date	2013-11-01(xsd:dateTime)
bibo:doi	10.1093/cid/cit725
bibo:pmid	24186906
has license	bronze-oa
sha1sum (hex)	5f88b4d6e65a19b84991526dab51391ff4acf08f
schema:url	https://doi.org/10.1093/cid/cit725
resource representing a document's title	The Natural History of Influenza Infection in the Severely Immunocompromised vs Nonimmunocompromised Hosts
has PubMed Central identifier	PMC3871797
has PubMed identifier	24186906
schema:publication	Clinical Infectious Diseases
resource representing a document's body	covid:5f88b4d6e65a19b84991526dab51391ff4acf08f#body_text
is schema:about of	named entity 'The Natural History' named entity 'HOSTS' named entity 'NATURAL HISTORY' named entity 'SEVERELY' named entity 'IMMUNOCOMPROMISED' named entity 'INFLUENZA INFECTION' named entity 'Influenza Infection' named entity 'H3N2' named entity 'antivirals' named entity 'influenza infection' named entity 'influenza viruses' named entity 'blood samples' named entity 'tachycardia' named entity 'vaccination' named entity 'dry cough' named entity 'lower respiratory tract' named entity 'TNF-α' named entity 'symptoms and signs' named entity 'infection' named entity 'immunological studies' named entity 'viral evolution' named entity 'A(H1N1)pdm09' named entity 'influenza' named entity 'interleukin 2' named entity 'interleukin 7' named entity 'influenza' named entity 'cytokine' named entity 'viruses' named entity 'H3N2' named entity 'dry cough' named entity 'infection' named entity 'chemotherapy' named entity 'influenza infection' named entity 'Viral' named entity 'antivirals' named entity 'immunocompromised' named entity 'pneumonia' named entity 'influenza' named entity 'influenza viruses' named entity 'viruses' named entity 'A(H1N1)pdm09' named entity 'neurologic' named entity 'immunosuppression' named entity 'physical exams' named entity 'GM-CSF' named entity 'immunocompromised' named entity 'immunocompromised' named entity 'virus' named entity 'immunocompromised patients' named entity 'influenza infection' named entity 'A(H1N1)pdm09' named entity 'comorbidities' named entity 'Cardiac abnormalities' named entity 'peramivir' named entity 'Viral' named entity 'Sanger sequencing' named entity 'pandemics' named entity 'interleukin 1β' named entity 'influenza infection' named entity 'intensive care' named entity 'mortality rate' named entity 'Clinicaltrials.gov' named entity 'influenza' named entity 'hypertension' named entity 'influenza' named entity 'MCP-1' named entity 'Washington Hospital Center' named entity 'antiviral' named entity 'immunosuppressive' named entity 'tumor'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software